The following announcement was written by DNAPrint Genomics:
SARASOTA, FL -- DNAPrint® Genomics (OTCBB: DNAG) has announced the release of the long-awaited EuroDNA(TM) 2.0 (http://ancestrybydna.com/welcome/productsandservices/eurodna/ancestrykit/) ancestry indicator, which complements DNAPrint®'s powerful line of ancestry testing products.
Richard Gabriel, Chief Executive Officer of DNAPrint® Genomics, sees many applications for EuroDNA(TM) 2.0. "Our customers have been requesting a more in-depth test, and we are excited to be able to give them our EuroDNA(TM) 2.0 test, which delivers more specific bio-geographical ancestry categories than our previous tests," Mr. Gabriel said.
DNAPrint®'s EuroDNA(TM) 2.0 clarifies European sub-ancestry by using 1,349 European Ancestry Informative Markers (AIMs). This test reports a person's proportional basic continental European ancestry using several categories: Southeastern Europe (Armenian, Jewish, Greek and some Italians); Iberian (Spanish, Portuguese); Basque (Spanish/French Pyrenees border); Continental European (German, Irish, English, Polish, Some French and Italian); and North Eastern European (Finnish). The EuroDNA(TM) 2.0 test is by far the most advanced genetic ancestry test yet to be offered to the public.
EuroDNA(TM) 2.0 provides more information than DNAPrint(TM)'s primary genealogy product, AncestryByDNA(TM) 2.5 (http://www.ancestrybydna.com/), which is a pan-chromosomal assay for genetic ancestry that uses just 176 AIMs. The new EuroDNA(TM) 2.0 test is also expected to provide greater sensitivity and accuracy than EuroDNA(TM) 1.0, which employed 320 AIMs. Some individuals who take AncestryByDNA(TM) 2.5 and/or EuroDNA(TM) 1.0 will find interesting, unexpected results and may desire to obtain the additional precision provided by EuroDNA(TM) 2.0's different, more extensive marker set.
Using complex statistical algorithms, AncestryByDNA(TM) 2.5 by itself can determine with confidence which of the four major bio-geographical ancestry groups -- sub-Saharan African, European, East Asian or Native American -- constitutes a person's genetic background. The test also determines the relative percentages in cases of admixed peoples. It is a useful method for those individuals or groups interested in obtaining a deeper understanding of their ancestry and lineage, or for certain people (i.e., some adoptees of mixed heritage) learning about their genetic ancestry.
"European" ancestry from AncestryByDNA(TM) 2.5 actually refers to a type of ancestry shared by people who derived from the fertile crescent of the Middle East some 50,000 years ago and spread to occupy Europe, the Middle East, parts of Eurasia and South Asia.
About DNAPrint(TM) Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.